References
- Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7-11. doi:10.1016/j.kisu.2021.11.003
- Sundström J, Bodegard J, Bollmann A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study. The Lancet Regional Health - Europe. 2022;20:100438. doi:10.1016/J.LANEPE.2022.100438
- Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021;143(11):1157-1172. doi:10.1161/CIRCULATIONAHA.120.050686
- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C yuan. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305. doi:10.1056/NEJMoa041031
- Vallianou NG, Mitesh S, Gkogkou A, Geladari E. Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship? Curr Cardiol Rev. 2019;15(1):55-63. doi:10.2174/1573403X14666180711124825
- Buckley LF, Schmidt IM, Verma A, et al. Associations Between Kidney Histopathologic Lesions and Incident Cardiovascular Disease in Adults With Chronic Kidney Disease. JAMA Cardiol. 2023;8(4):357-365. doi:10.1001/jamacardio.2023.0056
- Ocak G, Rookmaaker MB, Algra A, et al. Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study. Journal of Thrombosis and Haemostasis. 2018;16(1):65-73. doi:10.1111/jth.13904
- Sood MM, Bota SE, Mcarthur E, et al. The Three-Year Incidence of Major Hemorrhage among Older Adults Initiating Chronic Dialysis.; 2014. http://www.cjkhd.org/content/1/1/21
- Kuo CC, Kuo HW, Lee IM, Lee CT, Yang CY. The Risk of Upper Gastrointestinal Bleeding in Patients Treated with Hemodialysis: A Population-Based Cohort Study.; 2013. http://www.biomedcentral.com/1471-2369/14/15
- Liao JN, Chao TF, Liu CJ, et al. Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int. 2015;87(6):1209-1215. doi:10.1038/ki.2014.393
- Official JOurnal Of the InternatiOnal SOciety Of NephrOlOgy KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. www.publicationethics.org
- Christiansen CF, Schmidt M, Lamberg AL, et al. Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study. J Thromb Haemost. 2014;12(9):1449-1454. doi:10.1111/jth.12652
- Wanner C, Herzog CA, Turakhia MP, Conference Steering Committee. Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2018;94(2):231-234. doi:10.1016/j.kint.2018.05.005
- Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol. 2019;42(8):774-782. doi:10.1002/clc.23196
- Pawar P, Kota A, Sen I, et al. Chronic kidney disease and anticoagulation - Quick overview and practical guide. Indian Journal of Vascular and Endovascular Surgery. 2022;9(1):40. doi:10.4103/ijves.ijves_90_21
- Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2020;97(4):664-675. doi:10.1016/j.kint.2019.11.027
- Sy J, Hsiung JT, Edgett D, Kalantar-Zadeh K, Streja E, Lau WL. Cardiovascular and Bleeding Outcomes with Anticoagulants across Kidney Disease Stages: Analysis of a National US Cohort. Am J Nephrol. 2021;52(3):199-208. doi:10.1159/000514753
- Burlacu A, Genovesi S, Ortiz A, et al. Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrol Dial Transplant. 2019;34(6):923-933. doi:10.1093/ndt/gfz040
- Parker K, Thachil J. The use of direct oral anticoagulants in chronic kidney disease. Br J Haematol. 2018;183(2):170-184. doi:10.1111/bjh.15564
- Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1-S276. doi:10.1016/j.kint.2021.05.021
- Official JOurnal Of the InternatiOnal SOciety Of NephrOlOgy KDIGO Clinical Practice Guideline for Glomerulonephritis.; 2012. http://www.kidney-international.org
- Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. doi:10.1136/annrheumdis-2019-215213
- Dufrost V, Risse J, Zuily S, Wahl D. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature. Curr Rheumatol Rep. 2016;18(12):74. doi:10.1007/s11926-016-0623-7
- Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med. 2019;171(10):685-694. doi:10.7326/M19-0291
- Kronbichler A, Leierer J, Shin J Il, et al. Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2019;71(11):1888-1893. doi:10.1002/art.41017
- Carli G, Farsi A, Chiarini F, Lippolis D, Cortellini G. Hypersensitivity reactions to non-vitamin K oral anticoagulants - a review of literature and diagnostic work-up proposal. Eur Ann Allergy Clin Immunol. 2019;51(1):7-14. doi:10.23822/EurAnnACI.1764-1489.80
- Huang MJ, Wei RB, Wang Y, et al. Blood coagulation system in patients with chronic kidney disease: A prospective observational study. BMJ Open. 2017;7(5). doi:10.1136/bmjopen-2016-014294
- Baaten CCFMJ, Schröer JR, Floege J, et al. Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. Clinical Journal of the American Society of Nephrology. 2022;17(1):155-170. doi:10.2215/CJN.04100321
- Visseren FLJ, MacH F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484
- Taliercio JJ, Nakhoul G, Mehdi A, et al. Aspirin for Primary and Secondary Prevention of Mortality, Cardiovascular Disease, and Kidney Failure in the Chronic Renal Insufficiency Cohort (CRIC) Study. Kidney Med. 2022;4(11). doi:10.1016/j.xkme.2022.100547
- Wolfe R, Wetmore JB, Woods RL, et al. Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney Int. 2021;99(2):466-474. doi:10.1016/j.kint.2020.08.011
- Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: A post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56(12):956-965. doi:10.1016/j.jacc.2010.02.068
- Goicoechea M, de Vinuesa SG, Quiroga B, et al. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). Cardiovasc Drugs Ther. 2018;32(3):255-263. doi:10.1007/s10557-018-6802-1
- Floyd CN, Passacquale G, Ferro A. Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and Their Clinical Implications.
- Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost. 2007;98(4):838-843.
- Guo LZ, Kim MH, Shim CH, Choi SY, Serebruany VL. Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting. Eur Heart J Cardiovasc Pharmacother. 2016;2(3):145-151. doi:10.1093/ehjcvp/pvv052
- Baber U, Mehran R, Kirtane AJ, et al. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. Circ Cardiovasc Interv. 2015;8(6):e001683. doi:10.1161/CIRCINTERVENTIONS.115.001683
- Geara AS, Ayoub I, Abi Rached J, Siddique MN, Ghimire P, El-Sayegh S. Does hemodialysis affect clopidogrel resistance as measured by VerifyNow P2Y12 test? Am J Cardiol.2011; 107(7):1103-1104. doi:10.1016/j.amjcard.2011.01.003
- Melloni C, Cornel JH, Hafley G, et al. Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. Eur Heart J Acute Cardiovasc Care. 2016;5(6):443-454. doi:10.1177/2048872615598631
- Keltai M, Tonelli M, Mann JFE, et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil. 2007;14 (2):312-318.doi:10.1097/01.hjr.0000220582.19516.a6
- Best PJM, Steinhubl SR, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155(4):687-693. doi:10.1016/j.ahj.2007.10.046
- Trimarchi H, Young P, Forrester M, Schropp J, Pereyra H, Freixas E. Clopidogrel diminishes hemodialysis access graft thrombosis. J Vasc Access. 2005;6(1):29-33. doi:10.1177/112972980500600107
- Ghorbani A, Aalamshah M, Shahbazian H, Ehsanpour A, Aref A. Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian J Nephrol. 2009;19(2):57-61. doi:10.4103/0971-4065.53323
- Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA. 2008;299(18):2164-2171. doi:10.1001/jama.299.18.2164
- Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367. doi:10.1093/eurheartj/ehaa575
- Roe MT, Armstrong PW, Fox KAA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297-1309. doi:10.1056/NEJMoa1205512
- Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. doi:10.1056/NEJMoa0706482
- Baber U, Chandrasekhar J, Sartori S, et al. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention A Report From the PROMETHEUS Study.; 2017.
- James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056-1067. doi:10.1161/CIRCULATIONAHA.109.933796
- Mavrakanas TA, Kamal O, Charytan DM. Prasugrel and Ticagrelor in Patients with Drug-Eluting Stents and Kidney Failure. Clin J Am Soc Nephrol. 2021;16(5):757-764. doi:10.2215/CJN.12120720
- Laine M, Lemesle G, Burtey S, et al. TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial. Am Heart J. 2020;225:19-26. doi:10.1016/j.ahj.2020.04.013